Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhea-AI Summary
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 with a live conference call and webcast at 8:00 a.m. ET. Participants may register to join; joining 10 minutes early is recommended.
CEO David Meeker will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 at 11:10 a.m. ET. Both webcasts will be archived on Rhythm’s Investor Relations website; the earnings call archive will be available about two hours after the call and both recordings will remain for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RYTM gained 4.55%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $303M to the company's valuation, bringing the market cap to $6.97B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves, with ABVX and CYTK up while LEGN, AXSM, and NUVL were down, suggesting RYTM’s 2.09% gain was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Neutral | -3.8% | Announced CFO fireside chat at Guggenheim Biotech Summit with webcast access. |
| Jan 09 | Prelim revenues | Positive | +3.6% | Preliminary IMCIVREE Q4 and FY2025 revenue growth and detailed 2026 milestones. |
| Dec 11 | Phase 2 data | Positive | +12.3% | Preliminary Phase 2 PWS trial showed positive efficacy signal and safety consistency. |
| Dec 10 | Data call scheduled | Neutral | +4.0% | Scheduled webcast to disclose preliminary Phase 2 PWS data with replay details. |
| Nov 10 | Conference data | Positive | -2.7% | Presented multiple obesity datasets including strong TRANSCEND BMI reductions. |
Positive clinical and revenue updates often saw aligned gains, while logistics or even strong scientific data sometimes coincided with selling, indicating inconsistent reactions to news quality.
Over the last several months, Rhythm reported preliminary Q4/FY2025 revenue growth, multiple positive clinical data readouts, and conference participations. The Jan 9, 2026 revenue update and Dec 2025 PWS Phase 2 data both coincided with gains, while earlier ObesityWeek® 2025 data on Nov 10, 2025 saw a modest decline despite strong efficacy signals. Today’s release simply sets the date and access details for full 2025 results and another conference appearance, fitting into a pattern of frequent investor communications.
Market Pulse Summary
This announcement sets the timeline for Rhythm’s fourth quarter and full year 2025 results and highlights an additional investor touchpoint at the TD Cowen health care conference. In context of earlier preliminary revenue and clinical updates, investors now know when full audited figures and a broader corporate update will be provided. Key items to watch include confirmation of previously shared revenue trends, any updated guidance, and how management frames progress on Phase 3 programs and regulatory milestones.
AI-generated analysis. Not financial advice.
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.
To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026, at 11:10 a.m. ET.
Live webcasts of both the financial results conference call and the fireside chat will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at http://ir.rhythmtx.com/. The archived webcast of the financial results conference call will be available on Rhythm’s website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the TD Cowen webcast will also be available on the Rhythm website for 30 days following the presentation.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Setmelanotide Indication
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
- Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the release of our financial results and our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended September 30, 2025 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
dconnolly@rhythmtx.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
FAQ
When will Rhythm Pharmaceuticals (RYTM) report Q4 and full year 2025 results?
How can investors access the RYTM earnings call and webcast on February 26, 2026?
Will Rhythm (RYTM) provide an archived replay of the February 26, 2026 call?
When and where is Rhythm CEO David Meeker speaking at the TD Cowen conference?
What topics will Rhythm (RYTM) cover during the February 26, 2026 corporate update?
How long will the TD Cowen webcast and the earnings replay remain available on Rhythm’s site?
